Claim Ledger
86% answered
Did management answer the analysts?
12 analyst questions audited, 1 evaded or deflected.
View Claim Ledger →Cipla Ltd — Q2 FY26
Cipla delivered an all-time high quarterly revenue of INR 7,589 crore (+8% YoY) with a robust EBITDA margin of 25%, driven by broad-based growth across One India, US Generics, One Africa, and EMEU.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered an all-time high quarterly revenue of INR 7,589 crore (+8% YoY) with a robust EBITDA margin of 25%, driven by broad-based growth across One India, US Generics, One Africa, and EMEU. The US business contributed $233 million in revenue, with Cipla becoming the #1 player in the albuterol MDI market (22% share). The India branded business grew 7% YoY, with chronic mix improving to 61.8%. Management revised FY26 EBITDA margin guidance down to 22.75%-24% (from 23.5%-24.5%) due to higher R&D spend and declining Revlimid contribution. Key growth drivers include the tirzepatide (Yurpeak) launch in India, upcoming respiratory and peptide launches in the US, and continued momentum in EMEU. Risk: Revlimid revenue is expected to become immaterial from Q3, creating a near-term revenue gap that new launches may not fully offset.
सिप्ला ने इस तिमाही में अब तक का सबसे ज़्यादा कारोबार किया - 7,589 करोड़ रुपये (पिछले साल से 8% ज़्यादा)। कंपनी की कमाई पर मुनाफ़ा दर (EBITDA मार्जिन) 25% रही, जो अच्छा है। यह वृद्धि भारत, अमेरिका, अफ्रीका और यूरोप-मिडिल ईस्ट के कारोबार से आई। अमेरिका में 233 मिलियन डॉलर का कारोबार हुआ और सिप्ला अस्थमा की दवा (अल्ब्युटेरॉल MDI) में नंबर-1 बन गई (22% हिस्सेदारी)। भारत में ब्रांडेड दवाओं का कारोबार 7% बढ़ा, और पुरानी बीमारियों की दवाओं का हिस्सा 61.8% हो गया। कंपनी ने अगले साल के मुनाफ़े का अनुमान घटाकर 22.75%-24% कर दिया (पहले 23.5%-24.5% था), क्योंकि रिसर्च पर ज़्यादा खर्च होगा और रेवलिमिड दवा से कमाई घटेगी। आगे वृद्धि के लिए भारत में मोटापे की नई दवा (युरपीक), अमेरिका में सांस और पेप्टाइड दवाओं का लॉन्च अहम होगा। जोखिम: रेवलिमिड से कमाई तीसरी तिमाही से लगभग खत्म हो जाएगी, जिससे नई दवाएं पूरी भरपाई नहीं कर पाएंगी।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Revlimid revenue cliff
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Revenue
$233M
+8% YoY
Quarterly US generics revenue, driven by respiratory and lanreotide market share gains.
Albuterol MDI Market Share
22%
+?pp YoY
Cipla became the #1 player in the US albuterol MDI market as of Sep 2025.
Lanreotide Market Share
22%
+?pp YoY
Market share as of MAT August 2025, expected to continue increasing.
India Chronic Mix
61.8%
+?pp YoY
Chronic prescription mix improved YoY, reflecting focus on high-growth therapies.
What Changed vs Last Quarter
NEW
Generic Revlimid contribution immaterial from Q3 FY26
Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.
NEW
Launch of four major respiratory assets by CY26
Includes generic Advair in Q4 2026 and three peptide assets including liraglutide.
NEW
US revenue directional target of $1B next year
Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.
UPDATED
FY26 EBITDA margin guidance revised to 22.75%-24%
Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution.
DROPPED
US revenue target of ~$1 billion by FY27
CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27.
DROPPED
India branded business to grow in line with IPM in next three quarters
COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26.
DROPPED
Biosimilar launch in US expected in Q2 FY26
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
NEW RISK
Execution risk on US pipeline launches
Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.
NEW RISK
Tirzepatide exclusivity and competition
Potential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside.
RISK GONE
Indore facility reinspection risk
Indore facility is due for US FDA reinspection within the next year; any adverse outcome could disrupt US supplies.
RISK GONE
GLP-1 market competition and execution
Management acknowledged GLP-1 market will be crowded; Cipla's strategy is still evolving and may face challenges in capturing share.
🤫 Topics management stopped discussing
Mentioned in Q2 FY25, Q3 FY25, Q4 FY25
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
Mentioned in Q1 FY26, Q3 FY25
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
Mentioned in Q1 FY25, Q2 FY25
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Mentioned in Q1 FY25, Q2 FY25
Supply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.
Mentioned in Q2 FY25, Q3 FY25
Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.
Fast read
Guidance and risk preview
Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution.
Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near...
View Risks →